Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and v3.4.1 was removed as part of page versioning; this is an administrative update that does not alter study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T02:19:47.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding status notice at the top of the page and updated the version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T01:17:39.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    UI and metadata updates were made, including a glossary toggle and revised last-update/revision labels, while older labels were removed. These adjustments clarify navigation and provenance without altering the study data.
    Difference
    0.3%
    Check dated 2026-01-27T23:53:23.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now shown, replacing Revision: v3.3.3. No study content or details were modified.
    Difference
    0.1%
    Check dated 2026-01-14T02:14:56.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Added a Locations section listing Massachusetts sites for the study and updated the page revision to v3.3.3. Removed the older Massachusetts Locations entry and the HHS Vulnerability Disclosure link in the prior revision.
    Difference
    0.2%
    Check dated 2025-12-23T20:40:18.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The study locations were updated to three sites, adding Dana-Farber Cancer Institute in Boston, MA. The prior note indicating two locations was removed.
    Difference
    0.4%
    Check dated 2025-12-09T13:46:28.000Z thumbnail image

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.